My last article about Johnson & Johnson (NYSE: JNJ ) was published half a year ago – at the beginning of July 2024. And in my conclusion, I was rather optimistic about the business and rated the stock as a “Buy”:My analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large ca ...